Recombinant Anti-Human EGFR Antibody (Non-glycosylated) (CAT#: Gly-167LC)
This product is a non-glycosylated human monoclonal antibody. The antibody 2F8-HG has increased efficacy as well as decreased side effect, it specficfically binds to human EGFR and can be potentially used in the treatment of metastatic colorectal cancer.
Specific Inquiry
Subcellular Location and Protein Expression
Normal Tissue
RNA Expression
Figure 1 IF staining of human cell line A-431
(Immunofluorescent staining of human cell line A-431 shows localization to plasma membrane & cell junctions.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/144_E9_2_selected.jpg
(Immunofluorescent staining of human cell line A-431 shows localization to plasma membrane & cell junctions.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/144_E9_2_selected.jpg
Figure 2 IF staining of human cell line U-251 MG
(Immunofluorescent staining of human cell line U-251 MG shows localization to plasma membrane.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/143_E9_1_blue_red_green.jpg
(Immunofluorescent staining of human cell line U-251 MG shows localization to plasma membrane.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/143_E9_1_blue_red_green.jpg
Figure 3 Colon
(Glandular cells
Staining:Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_9_3.jpg
(Glandular cells
Staining:Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_9_3.jpg
Figure 4 Liver
(Cholangiocytes
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_7_4.jpg
(Cholangiocytes
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_7_4.jpg
Figure 5 Kidney
(Bowman's capsule
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%
Collecting ducts
Staining:Medium
Intensity: Strong
Quantity: <25%
Distal tubules
Staining:Medium
Intensity: Strong
Quantity: <25%
Proximal tubules (cell body)
Staining:Medium
Intensity: Strong
Quantity: <25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_9_5.jpg
(Bowman's capsule
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%
Collecting ducts
Staining:Medium
Intensity: Strong
Quantity: <25%
Distal tubules
Staining:Medium
Intensity: Strong
Quantity: <25%
Proximal tubules (cell body)
Staining:Medium
Intensity: Strong
Quantity: <25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_9_5.jpg
Figure 6 Testis
(Leydig cells
Staining:Medium
Intensity: Moderate
Quantity:>75%
Pachytene spermatocytes
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%
Round or early spermatids
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_6_6.jpg
(Leydig cells
Staining:Medium
Intensity: Moderate
Quantity:>75%
Pachytene spermatocytes
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%
Round or early spermatids
Staining:Medium
Intensity: Moderate
Quantity: 75%-25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_6_6.jpg
Figure 7 Placenta
(Cytotrophoblasts
Staining:High
Intensity: Strong
Quantity:>75%
Decidual cells
Staining:Medium
Intensity: Moderate
Quantity:>75%
Hofbauer cells
Staining:High
Intensity: Strong
Quantity:>75%
Syncytiotrophoblasts - cell body
Staining:High
Intensity: Strong
Quantity:>75%
Syncytiotrophoblasts - microvilli
Staining:High
Intensity: Strong)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_1_7.jpg
(Cytotrophoblasts
Staining:High
Intensity: Strong
Quantity:>75%
Decidual cells
Staining:Medium
Intensity: Moderate
Quantity:>75%
Hofbauer cells
Staining:High
Intensity: Strong
Quantity:>75%
Syncytiotrophoblasts - cell body
Staining:High
Intensity: Strong
Quantity:>75%
Syncytiotrophoblasts - microvilli
Staining:High
Intensity: Strong)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_1_7.jpg
Figure 8 Lymph node
(Non-germinal center cells
Staining:Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_7_8.jpg
(Non-germinal center cells
Staining:Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/18530/41191_A_7_8.jpg
Figure 9 RNA cell line category: Cell line enriched (A-431)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000146648-EGFR
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000146648-EGFR
Glyco-engineering
- Activity
- Increased efficacy and/or decreased side effects
Specifications
- Target
- EGFR (Epidermal growth factor receptor)
- Host Species
- Human
- Type
- Human antibody
- Specificity
- Human
- Antibody Isotype
- IgG
- Clone
- 2F8-HG
- Applications
- ELISA
Target
- Alternative Names
- EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1;
- Related Disease
- Metastatic colorectal cancer
- Gene ID
- 1956
- UniProt ID
- P00533
Related Resources
Bladder Cancer
Non-small Cell Lung Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Cushing Syndrome
JAK-STAT Signaling Pathway
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "EGFR"
Select a product category from the dropdown menu below to view related products.
Please select product type
Chimeric Antibody
Single-domain Antibody
Humanized Antibody
Recombinant Antibody
Mouse Antibody
Human Antibody
Fc Glycosylation
High-mannose Glycoform
Chicken IgY Antibody
MHC Tetramer for Cancer
Neutralizing Antibody
Rabbit Monoclonal Antibody
scFv Fragment Antibody
ADCC Enhanced Antibody
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-750 | Anti-EGFR/HER1 Recombinant Antibody (Futuximab/Zatuximab) | Neut, ELISA, IF, IP, FuncS, FC, WB | IgG1 - kappa |
| TAB-003 | Anti-Human EGFR Recombinant Antibody (Cetuximab) | IF, IP, Neut, FuncS, ELISA, FC, ICC | IgG1 - kappa |
| TAB-H49 | Anti-Human EGFR Recombinant Antibody (Modotuximab) | FuncS, IF, Neut, ELISA, FC, IP, IHC | IgG1 - kappa |
| TAB-308MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-308MZ-F(E)) | ELISA, FC | Chimeric antibody (mouse/human) |
| PABX-051-F (E) | Recombinant Mouse Anti-EGFR Antibody Fab Fragment (Matuzumab) | WB, Neut, FuncS | Fab |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for Gly-167LC. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: Neut, Inhib, FC, ELISA
Application: ELISA, FC, IF, WB
Application: ELISA, Inhib, FuncS
Application: ELISA, WB, IF, FC, IP
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
